



## CLINICAL INSIGHTS

*EXCEL Division of Blue Cross Laboratories*

**ETERBA-MAD TAB/ ETERNA SYRUP/ ETERNA INJ**

**Issue I, No.2, 2026**

### **Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis**

*Freedman BS et.al; N Engl J Med; 2025 Jul 17;393(3):255-266.*

- A double-blind, randomized superiority trial was conducted to check the outcomes of Ondansetron in children having gastroenteritis-associated vomiting.
- A total of 1030 children from 6 months to less than 18 years of age underwent randomization.
- In response to persistent vomiting within the first 48 hours following enrollment, six doses of oral ondansetron or placebo were given; 5.1% of the ondansetron group and 12.5% of the placebo group experienced moderate-to-severe gastroenteritis.
- Ondansetron had fewer vomiting episodes overall within 48 hours after enrollment than placebo. Additionally, there was no significant difference in the incidence of adverse events between the groups.

**Compared to a placebo, Ondansetron decreased the incidence of moderate-to-severe gastroenteritis in children who had gastroenteritis-related vomiting over the seven days that followed an ER visit.**

